ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Plans CHF500 Million New Manufacturing Facility

ZURICH -(Dow Jones)- Swiss pharmaceutical company Novartis AG (NVS) said Monday it is planning to invest over 500 million Swiss francs ($550 million) building a new manufacturing facility in Switzerland. MAIN FACTS: -The company said the investment underlines the long-term strategy of Novartis to establish a worldwide manufacturing network of technology centers. -The new production site in Stein, Switzerland, is expected to be fully operational by end of 2016. -"This investment is further strengthening the importance of Stein as Manufacturing Center of Excellence for sterile and solid dosage forms and will play a key role in our global production network," said Joseph Jimenez, CEO of Novartis. "It also strengthens our presence in Switzerland, which remains a center of key importance for Novartis." -The Stein site in Canton Aargau is the largest production facility of the Pharmaceuticals Division. Every year, the approximately 1,400 associates at the site produce over 4.1 billion tablets, capsules, ampoules, prefilled syringes, vials and transdermal therapeutic systems, which are exported to over 150 countries. -The new set-up will allow Novartis to adapt its production capacity more quickly depending on an evolving portfolio and market demand. The center will serve approximately 150 markets globally. -Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals
06/24/201511:22:00Hagens Berman: Class Action Alleges Novartis Gleevec Patent Infringement...
06/22/201518:35:21ADRs End Higher; National Bank of Greece Rises
06/22/201507:47:44GlaxoSmithKline Sells Meningitis Vaccines to Pfizer For EUR115...
06/21/201511:06:03What Is Cancer Immunotherapy?
06/19/201511:38:07Novartis CEO: Roche Stake Would No Longer Have to Be Sold at...
06/18/201518:40:20ADRs End Higher; Telecom Italia Rises
06/18/201515:50:25Teva's Copaxone Patent Loses Again
06/17/201509:04:025 Healthcare Stocks for Dividend Lovers
06/14/201508:03:023 Big Healthcare Trends Wall Street Is Overlooking
06/13/201507:18:021 Drug Will Make or Break These 3 Biotech Stocks
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201510:05:06Cancer Stocks: 2 to Sell, 1 to Buy
06/10/201508:04:03Stocks to Watch in Animal Health: Zoetis and WOOF Lead the Pack
06/08/201519:01:02Google Inc Founder Sergey Brin Defends "Moonshots" to Shareholders
06/08/201507:24:023 Big Pharma Dividend Stocks That Are Dragging Down Your Returns
05/31/201513:03:02Stocks To Watch in Biotech
05/31/201510:19:03Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad